Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 64   

Articles published

ARNA 3.90 +0.12 (3.17%)
price chart
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Fights for Share of Weight-loss Pill ...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA, ARNA message board) is expected to launch its patented Belviq treatment early next year, but there are some doubts that by that time Vivus, Inc. (NASDAQ:VVUS) will have made its Qsymia something of a ...
Related articles »  
Is Arena The Next Alexion?
There was so much promise for the company and their recently approved drug Provenge that the valuation reached $6B for the company even before the product could hit the market. Many believers held the stock based on their ... Even though Alexion ...
Related articles »  
With Arena, Patience Is A Virtue
Investors in Arena Pharmaceuticals (NASDAQ:ARNA) have been patient for quite some time. Early investors ... Orexigen Therapeutics (NASDAQ:OREX) is an interesting company to watch because it could very well follow in the footsteps of Arena and Vivus.
Arena Pharmaceuticals, Vivus Inc, and the Weight-loss Craze  Insider Monkey (blog)
Related articles »  
Heroes And Zeros: Arena Pharmaceuticals And Avanir Pharmaceuticals
Arena Pharmaceuticals is a clinical stage biopharmaceutical company that has discovered, developed, and moved the first anti-obesity drug through FDA approval in the last 13 years in June of 2012.
Acadia Pharmaceuticals Poised For 100% Gain By December
... a company's prospects and affording investors willing to look beyond the conventional thinking an opportunity for substantial gains can be found in the positive advisory committee vote and subsequent approval of Arena Pharmaceuticals' (NASDAQ:ARNA) ...
Arena: DEA Schedule IV Will Make Belviq The Obesity Blockbuster Drug
In addition, Arena comes with some enticing benefits for a pharmaceutical suitor - 10 year Swiss Tax Haven and R&D Write-offs.
Related articles »  
500 Million Reasons to Bet on the Future of Mannkind (MNKD, ARNA,AMGN)
... drug developer operating in the biotech sector along with Amgen (NASDAQ: AMGN) and Arena Pharmaceuticals (NASDAQ: ARNA). As uber financier Mike Milken has pointed out, the capital structure is very important for a company in rewarding investors.
Obesity Drugs Gain Attention on FDA Backing for Therapies
Third Rock Ventures is an early backer of Zafgen Inc., a biotechnology company in mid-stage trials of a therapy to treat obesity. The Food and Drug Administration cleared Belviq, from Arena Pharmaceuticals Inc. (ARNA:US) and Eisai Co. (4523), in June ...
Vivus Shares Feel The Pain: Blockbuster Diet Drug Likely Won't Be Sold ...  Forbes
Related articles »  
Arthritis drug kick-starts Rigel, partner
Rigel Pharmaceuticals Inc. is in strange territory. After spending nearly $700 million over 16 years developing drugs, the low-key South San Francisco biotech company has an experimental rheumatoid arthritis drug swiftly heading toward a date with the FDA.
Dr. Jean-Paul Castaigne, CEO of Angiochem
Yet the most exciting developments for Angiochem this year have been in the rare-diseases arena. The company raised its profile and brought publicity to its preclinical efforts in transporting enzyme drugs for orphan disorders into the brain in ...